Tredje AP fonden Acquires 60,000 Shares of Becton, Dickinson and Company $BDX

Tredje AP fonden grew its stake in Becton, Dickinson and Company (NYSE:BDX) by 28.3% during the third quarter, HoldingsChannel.com reports. The firm owned 271,720 shares of the medical instruments supplier’s stock after buying an additional 60,000 shares during the period. Tredje AP fonden’s holdings in Becton, Dickinson and Company were worth $50,858,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. SOA Wealth Advisors LLC. boosted its holdings in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 95 shares during the last quarter. Activest Wealth Management raised its position in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares during the period. Bell Investment Advisors Inc boosted its stake in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 128 shares during the last quarter. Cornerstone Planning Group LLC boosted its stake in Becton, Dickinson and Company by 463.3% during the 3rd quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 139 shares during the last quarter. Finally, Grey Fox Wealth Advisors LLC acquired a new position in Becton, Dickinson and Company during the third quarter valued at approximately $32,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on BDX. Piper Sandler reiterated a “neutral” rating and issued a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. Jefferies Financial Group dropped their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Morgan Stanley raised their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, Stifel Nicolaus lifted their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $195.46.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the completion of the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,416 shares of company stock valued at $675,557 in the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $185.43 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The firm has a market cap of $52.80 billion, a price-to-earnings ratio of 30.25, a price-to-earnings-growth ratio of 13.23 and a beta of 0.25. The stock’s 50-day moving average is $197.33 and its 200-day moving average is $192.24. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $185.50.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is currently 68.52%.

Becton, Dickinson and Company declared that its board has authorized a share buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.